Compare Datadog Inc (DDOG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Merck & Co., Inc. — how do they compare? Datadog Inc trades at $293.46 (market cap $98.31B), while Merck & Co., Inc. trades at $145.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Datadog Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Merck & Co., Inc. for 98 Days on average.
| DDOG | MRK | |
|---|---|---|
Market Cap | $98.31B | $351.28B |
Volume | 2,936,660 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $288.15 | $156.43 |
52-Week Low | $102.62 | $82.49 |
Typical Hold Time | 76 Days | 98 Days |
Enterprise Value | $94.61B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $293.26, up 8.08% in the last session, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth from $2.7B in 2024 to $3.4B in 2025. Recent news highlights accelerating AI and enterprise customer expansion, with FBN Securities initiating coverage with an Outperform rating.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and accelerating AI-driven growth, though elevated valuation ratios (P/E 547.6, P/S 25.33) pose risks if growth moderates. Key risks include competitive pressure in cloud monitoring and dependence on enterprise spending cycles. The stock trades above the $276.10 consensus target, suggesting near-term upside may be limited despite bullish sentiment.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
